|
Aug 1
|
Gilead Sciences (GILD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
|
|
Jul 30
|
Compugen receives FDA approval for Phase I trial of solid tumour treatment
|
|
Jul 29
|
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
|
|
Jul 28
|
Gilead Sciences, Inc.'s (NASDAQ:GILD) one-year returns climbed after last week's 6.1% gain, institutional investors must be happy
|
|
Jul 25
|
Gilead Sciences to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024
|
|
Jul 25
|
Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline
|
|
Jul 25
|
3 Stocks That Can Help You to Get Richer in 2024 and Beyond
|
|
Jul 24
|
Full Efficacy and Safety Results for Gilead Investigational Twice-Yearly Lenacapavir for HIV Prevention Presented at AIDS 2024
|
|
Jul 23
|
Invest $50K in CVS Health and Gilead Sciences to Become a Dividend Millionaire
|
|
Jul 23
|
ViiV Healthcare’s Dovato as effective as Biktarvy in Phase IV HIV trial
|
|
Jul 23
|
Nanotechnology in medicine: Who are the leading public companies?
|
|
Jul 22
|
Gilead Sciences (GILD) Stock Declines While Market Improves: Some Information for Investors
|
|
Jun 26
|
Recent uptick might appease Gilead Sciences, Inc. (NASDAQ:GILD) institutional owners after losing 4.6% over the past year
|
|
Jun 25
|
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
|
|
Jun 24
|
The Zacks Analyst Blog Highlights Abbott Laboratories, BP, Gilead Sciences, Smith-Midland and Crimson Wine
|
|
Jun 21
|
Why A Broken Wing Butterfly Might Make Money In Gilead Sciences Stock
|
|
Jun 21
|
US indexes open mixed, pharmaceutical stocks climb: Morning Brief
|
|
Jun 21
|
Gilead sees encouraging results from shot to prevent HIV
|
|
Jun 21
|
Gilead (GILD) Up as Twice-Yearly HIV Shot Prevents Infection
|
|
Jun 21
|
Defying the Norms: 3 High P/E Stocks With Room to Run
|